SOLICITATION DOCUMENT Clause Samples
The SOLICITATION DOCUMENT clause defines the official set of documents issued by a party, typically a buyer or contracting authority, to invite bids or proposals from potential suppliers or contractors. This clause outlines what constitutes the solicitation package, which may include instructions to bidders, specifications, evaluation criteria, and contract terms. By clearly identifying the documents that form the basis of the solicitation, this clause ensures all parties are aware of the requirements and procedures, thereby promoting transparency and consistency in the procurement process.
SOLICITATION DOCUMENT. Exempt – Governmental Entity SECTION IV.
SOLICITATION DOCUMENT. Exempt - Governmental Entity N. All invoices will reference the Purchase Order Number.
A. TREATMENT CONSIDERATIONS The medical literature supports the use of opioid substitution therapy as first-line treatment for patients with opioid use disorders. Substance Abuse and Mental Health Services Administration (SAMHSA), American Society of Addiction Medicine (ASAM) and the Veterans Administration (VA) indicate that extended-release injectable naltrexone may be an acceptable alternative to opioid substitution therapy in selected patients. Careful patient selection is essential in order to maximize the chance of long-term treatment success and to minimize the risk of adverse outcomes including relapse and overdose. Several organizations, including SAMHSAi, VAii, ASAMiii and Providers’ Clinical Support System for Medication Assisted Treatment (PCSS-MAT)iv have published guidance on which patients may be the best candidates for treatment with extended-release injectable naltrexone. Patient selection criteria based on that guidance and on a review of the other available literature are included below. These criteria are intended as guidelines and should not be considered a substitute for the clinical judgment of the treating physician. The optimal duration of treatment with extended-release injectable naltrexone has not been determined. Most studies have been based on 6 months of medication, but data on long-term outcomes is lacking. The decision to discontinue medication must be determined on a case-by- case basis and in conjunction with patient preference, taking into account the relative risks and benefits. As with other forms of medication-assisted treatment (MAT), extended-release injectable naltrexone must only be used as part of a comprehensive program of treatment that includes counseling and behavioral therapy. Patients should be encouraged to participate in recovery- related activities in addition to formal counseling.
B. PHYSICIAN EDUCATION REQUIREMENTS Prior to initiation of treatment with extended-release injectable naltrexone, the ordering physician must gain a thorough understanding of the use of this medication in the treatment of patients with opioid use disorder. The treating physician must:
1. Become familiar with the published guidelines for the use of this medication, such as those by ▇▇▇▇▇▇, ASAM and the VA;
2. Become familiar with and follow the Food & Drug Administration (FDA) prescribing information, REMS and manufacturer’s recommendations r...
SOLICITATION DOCUMENT. Proprietary/Sole Source purchase.
SOLICITATION DOCUMENT. Exempt - Governmental Entity J. All invoices will reference the Purchase Order Number.
A. Funding from The United States Health and Humans Services (HHS) and the Substance Abuse and Mental Health Services Administration (SAMHSA) fund the HHSC Substance Use Disorder project(s), which includes this contract.
B. This contract is funded with the Catalog of Federal Domestic Assistance (CFDA) funds, Texas Targeted Opioid Response (TTOR) State Targeted Response (STR) and State Opioid Response (SOR) grants, CFDA 93.788
C. The total reimbursements for the contract are as follows:
1. In Fiscal Year 2020, the total reimbursements will not exceed $4,515,660.00, for the term September 1, 2019 through September 29, 2020. The funding is allocated as follows:
a. TTOR STR grant allocation is $3,010,440.00, for the term September 1, 2019 through April 30, 2020:
b. TTOR SOR grant allocation is $1,505,220.00, for the term May 1, 2020 through August 31, 2020.
2. In Fiscal Year 2021, the total reimbursements will not exceed $376,305.00, for the term September 1, 2020 through September 29, 2020. The funding is allocated from the TTOR SOR grant funds.
a. TTOR SOR grant allocation is $326,502.00, for the term September 1, 2020 through September 29, 2020.
D. Performing Agency Share (Match) TTOR grant funds do not require match.
E. Performing Agency will submit invoices to the System Agency through the Clinical Management for Behavioral Health Services (CMBHS) system monthly.
F. Any unexpended balance associated with any other System Agency Contract may not be applied to this System Agency Contract.
G. System Agency funded capacity is defined as the stated number of clients that will be concurrently served as determined by this Contract.
H. Clinic Numbers must be approved by the Assigned Contract Manager before billing can occur. Clinic Change Request form is located at: ▇▇▇▇://▇▇▇.▇▇▇▇.▇▇▇▇▇.▇▇▇/sa/For-
I. Service Types with no associated Amount will be paid from the preceding Service Type with an associated Amount.
SOLICITATION DOCUMENT. The Department of State Health Services (DSHS) Substance Abuse Intervention Programs Request for Proposals issued on November 5, 2012, RFP# SA/INTV-540.1. None
SOLICITATION DOCUMENT. A document developed by the County to obtain bids, proposals, and other information from bidders/proposers.